Application of Gross Tissue Response System in Gastric Cancer After Neoadjuvant Chemotherapy: A Primary Report of a Prospective Cohort Study
暂无分享,去创建一个
Zongguang Zhou | Han Yang | Jian-Ping Liu | Yun Qin | Xin-Zu Chen | Weihan Zhang | Du He | Kai Liu | Xiao-Long Chen | Jian-kun Hu | R. Ge | Weiwen Zhang | Kun Yang | Bo-qiang Peng
[1] Yuquan Wei,et al. Genomic evolution and diverse models of systemic metastases in colorectal cancer , 2021, Gut.
[2] J. Ji,et al. Assessment of Laparoscopic Distal Gastrectomy After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Randomized Clinical Trial. , 2019, JAMA surgery.
[3] Jong Hoon Kim,et al. Local excision in mid-to-low rectal cancer patients who revealed clinically total or near-total regression after preoperative chemoradiotherapy; a proposed trial , 2019, BMC Cancer.
[4] Wei Xiong,et al. Analysis of status and countermeasures of cancer incidence and mortality in China , 2019, Science China Life Sciences.
[5] R. Komaki,et al. A pooled analysis of individual patient data (IPD) of concurrent chemoradiotherapy for limited-stage small cell lung cancer (LS-SCLC) in elderly compared to younger patients (pts) who participated in US National Cancer Institute cooperative group studies. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] Zongguang Zhou,et al. [Establishment and preliminary application of tissue response grading system following neoadjuvant chemotherapy]. , 2018, Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery.
[7] J. Ajani. Faculty Opinions recommendation of Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[8] T. Hothorn,et al. Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer , 2017, Journal of the National Cancer Institute.
[9] R. Agha,et al. The STROCSS statement: Strengthening the Reporting of Cohort Studies in Surgery. , 2017, International journal of surgery.
[10] H. Grabsch,et al. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial , 2017, The Lancet. Oncology.
[11] R. Sant'ana,et al. Histopathological regression of gastric adenocarcinoma after neoadjuvant therapy: a critical review , 2017, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[12] J. Sul,et al. Clinical Outcome of Doublet and Triplet Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer. , 2016, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.
[13] Chao Lu,et al. Retrospective study , 2016, Medicine.
[14] Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4) , 2016, Gastric Cancer.
[15] W. Kang,et al. Effect of Neoadjuvant Chemotherapy Treatment on Prognosis of Patients with Advanced Gastric Cancer: a Retrospective Study. , 2015, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih.
[16] A. Setser,et al. Grading Dermatologic Adverse Events in Clinical Trials Using CTCAE v4.0 , 2013 .
[17] J. Reynolds,et al. Classification of Pathologic Response to Neoadjuvant Therapy in Esophageal and Junctional Cancer: Assessment of Existing Measures and Proposal of a Novel 3-Point Standard , 2013, Annals of surgery.
[18] Laura H. Tang,et al. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma , 2011, British Journal of Cancer.
[19] J. Pignon,et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] R. Langer,et al. Significance of Histopathological Tumor Regression After Neoadjuvant Chemotherapy in Gastric Adenocarcinomas: A Summary of 480 Cases , 2011, Annals of surgery.
[21] Karin Haustermans,et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. , 2010, The Lancet. Oncology.
[22] T. Henkel,et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study , 2008, Histopathology.
[23] L. Rubbia‐Brandt,et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] C. V. D. van de Velde,et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.
[25] H. Höfler,et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy , 2003, Cancer.
[26] C. Aring,et al. A CRITICAL REVIEW , 1939, Journal of neurology and psychiatry.
[27] D. Brizel,et al. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .
[28] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[29] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.